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TO THE EDITOR
Bone marrow (BM) consists of the hematopoietic stem cell (HSC) compartment and the microenvironment which regulates hematopoiesis. Microenvironment is constituted by stromal cells, adipocytes and osteoblasts, all derived from the mesenchymal stem cells (MSC).
1 Animal studies have indicated that MSC can engraft in BM. 2 In humans a study on children with osteogenesis imperfecta receiving allogeneic MSC indicated the presence of donor cells on in vitro osteoblast culture albeit at a low level. 3 MSC have also immuno suppressive properties and can induce tolerance. 4 Although severe aplastic anemia (SAA) is an auto-immune disease where the stroma usually functions normally, damage of the microenvironment has been observed in a subset of SAA patients. 5 We report here a 68-year-old woman patient with end stage SAA refractory to administration of growth factors, cyclosporine A, antithymocyte globuline and ineligible for an allogeneic hematopoietic stem cell transplantation (HSCT). This patient received two infusions of allogeneic MSC, in order to improve a possible defective BM stroma, to stimulate hypothetical residual HSC by local production of hematopoietic growth factors, and to gain benefit from the immunosuppressive properties of MSC on the auto-immune mechanism of SAA. Forty ml of BM was harvested from the posterior iliac crest of the son of the patient. BM mononuclear cells were seeded in long-term marrow culture for ex vivo MSC isolation and expansion. 6 A total of 10 × 10 6 MSC/kg of patient body weight was obtained. The MSC purity was assessed by flow cytometry: cells were SH2, SH3 positive and CD34, CD45 negative. The day before MSC infusion, the patient received a light conditioning regimen comprising cyclophosphamide 20 mg/kg in order to allow engraftment of allogeneic MSC. On the following day, 2 × 10 6 MSC/kg were infused intravenously. Three weeks later no recovery of hematopoieisis was observed; the clinical condition of the patient worsened mainly due to progression of a previous invasive fungal infection. A second infusion of 6 × 10 6 MSC/kg without any conditioning regimen was then performed. Thirty-four days after the second infusion, no effect on hematopoiesis was observed and the patient died from invasive fungal infection. BM analysis showed BM partial recovery of stroma and allogeneic MSC were detected in the recipient BM, suggesting engraftment.
Changes in BM stroma were documented by BM biopsies and colony-forming unit fibroblast (CFU-F) clonogenic assays for stromal cells. Before MSC infusion, the biopsy showed no residual hematopoietic tissue, interstitial hemorrhage, edema, adipocytic necrosis and no stromal cells as suggested by the absence of positive cell immunostaining with vimentine ( Figure 1 ). After MSC infusion, although there was no recovery of hematopoietic tissue, interstitial hemorrhage, edema and adipocytic necrosis all disappeared, stromal spindleshaped cells became visible with vimentin immunostaining (Figure 2 ).
Figure 1
Bone marrow histology with vimentin staining before MSC infusion showed the virtual disappearance of the supportive scaffolding microenvironment confirmed by the absence of positive cell with the Vimentin immunostaining. The rare positive cells were endothelial cells (arrow).
Figure 2
After MSC infusion bone marrow changes were shown by the presence of stromal spindle cells (arrows) and adipocytes (mesenchymal derived) all stained with vimentin.
In vitro CFU-F colonies became detectable after MSC infusion: before MSC infusion CFU-F was detectable; 3 weeks after the first infusion, 5 CFU-F/10 6 seeded cells were visible on day 14 of in vitro culture; 1 month after the second infusion, 7 CFU-F/10 6 seeded cells were visible earlier, on day 8 of in vitro culture.
Chimerism study was performed by real time PCR and was done on two whole BM biopsies harvested 3 weeks after the first infusion and 1 month after the second infusion. The SRY gene primer was used to detect male DNA. This PCR (sensitivity: 10 pg of male DNA) was performed on 100 ng of spectrophotometrically quantitated DNA. The presence of SRY gene was detected on whole BM after both MSC infusions. The level of the positive signal was higher after the second infusion than after the first and above the 10 pg control male DNA (Figure 3) . In contrast to the whole BM biopsies which contained male DNA, real time PCR could not detect male DNA in the in vitro cultures which all remained of recipient origin. This discrepancy between chimerism results in BM biopsy and in liquid in vitro culture has already been observed in baboons 2 and in a mouse model where MSC were shown to be present at a higher incidence in the compact bone as compared to the liquid marrow. 7 These observations including our patient suggest that allogeneic MSC are located in the endosteum and not in the marrow aspirates from which in vitro cultures are performed.
This observation shows that allogeneic MSC can be safely infused intravenously without inducing any side-effect and/or acute GVHD. The role of these cells in combination with hematopoietic stem cell transplantation is currently being investigated in an effect to accelerate
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Figure 3
Chimerism study from whole bone marrow samples by real time PCR for the SRY gene for detetion of male DNA. The presence of donor DNA in the recipient whole bone marrow was detected. The level of positive signal was higher after the second MSC infusion (curve II) and above to the 10 pg male DNA control. Curve I corresponds to a positive control of 100 ng male DNA, curve II to recipient bone marrow after the second MSC infusion, curve III to a positive control of 10 pg male DNA, curve IV to recipient bone marrow after the first MSC infusion; curve V to a negative control (normal female DNA) and curve VI to patient peripheral blood. hematopoietic recovery, reduce the risk of graft failure and reduce the incidence of acute GVHD. Previous studies in animals and in human have revealed that the level of chimerism of allogeneic MSC is always low but sufficient to induce a biological effect. 3 In our patient it is conceivable that donor MSC engrafted at a low level in the compact bone and then through cytokine production indirectly recruited recipient residual MSC which then proliferated to repopulate the stroma. This is suggested by the CFU-F assay which showed no detectable colony before MSC infusion but the presence of colonies after MSC infusion. Interpretation of the results with histology is more difficult because SAA is a patchy disease and morphological variations in BM findings frequently observed over time can be explained by sampling alone.
In a few women with male children, male fetal progenitor cells CD34 + CD38 + have been shown to persist in maternal blood, infact, for as long as 27 years post partum in a woman who had given birth to six male infants. 8 Therefore one might question our detection of the SRY gene in bone as reflecting the persistence of such a microchimerism related to male fetal progenitor cells rather than attesting to real engraftment of adult male MSC in the endosteum. Although pre-MSC infusion PCR on patient bone was not performed, the blood post-MSC infusion of our patient tested with quantitative PCR was SRY negative (curve VI of Figure 3 ). In addition, the level of SRY DNA increased from the first to the second transplant and the value obtained after the second transplant (Ͼ10 pg male DNA) was higher than the microchimerism reported in maternal blood. Histological changes and improvement of CFU-F assays are additional arguments for a biological effect and engraftment of allogeneic MSC.
This observation also raises the problem of the dose of MSC infused. We observed that after the second infusion which contained 6 × 10 6 MSC/kg, the level of chimerism was higher and the detection of CFU-F earlier, than after the first infusion which contained 2 × 10 6 MSC/kg. Further studies will be necessary to investigate dose effect in allogeneic MSC transplantation.
The role of MSC infusion in marrow failure including SAA needs further studies. In the present patient the benefit of allogeneic MSC infusion was only partial: BM stroma improved but not hematopoiesis. This observation may underline the necessity to combine, when no residual hematopoitic tissue is detectable, allogeneic MSC with HSC transplantation if feasible. In this large series, seven patients aged 15-50 years were shown to carry an ETV6/AML1 signal co-localization using commercial probes, giving a 4.4% incidence for this lesion, the highest so far reported in adult ALL patients.
2,3 Interestingly, one of the two patients tested by RT-PCR did not show the expected ETV6/AML1 fusion product, raising the possibility that FISH may reveal cases with alternative breakpoints which are missed by PCR. 1 We performed a centralized cytogenetic and molecular genetic analysis in 162 consecutive patients with ALL (71.6% B-ALL; 28.4% T-ALL) in the 14-85 years age range (median age 34), 135 of whom were enrolled in the 0496 GIMEMA trial. Fresh bone marrow (BM) samples were shipped by overnight courier and processed by established short-term culture methods for karyotyping. In 135 cases part of the cells were also submitted to standard procedures for the detection of the following aberrations by Southern blotting and by RT-PCR methods:
4 MLL rearrangement, BCR/ABL fusion, E2A/PBX1 fusion, ETV6/AML1 fusion. All cases were also studied by FISH using the Vysis dual-color probe combination (Vysis, Downer's Grove, IL, USA) for the detection of the t(12;21) and of the corresponding ETV6/AML1 fusion. The expected normal signal configuration consisting of two separate red and two green signals was observed in Ͼ95% of nuclei in five normal controls, indicating a high hybridization efficiency with a Ͻ1.5% false red/green fusion rate.
In this series no case with evidence of t(12;21) or ETV6/AML1 fusion by FISH analysis was found (at least 200 cells observed in Ͼ90% of the cases; >100 cells in the remaining cases); likewise, no patient carrying a hybrid ETV6/AML1 transcript was detected by RT-PCR. Thus, our findings do not support the suggestion that FISH may be more sensitive than molecular methods in the detection of this aberration, in line with previous observations on a limited number of cases which have shown concordant results by FISH and molecular genetics.
2, 5, 6 The difference in the incidence of this genetic lesion between our series and that of Jabbar Al-Obaidi et al is statistically significant (P = 0.009). Since these experiments were performed by experienced personnel in referral laboratories, technical errors which may account for the different incidence of this aberration in the Italian and in the UK series are highly unlikely; we suggest that geographic heterogeneity in the genotype of adult ALL may be a reasonable explanation for this observation. Interestingly, the incidence of ETV6/AML1 fusion in adult ALL studied in France, Spain and Italy appears to fall in the 0-1% range, 2,6 whereas a 3% incidence has been reported in 1996 by Aguiar and colleagues who analyzed 101 ALL in the UK. 3 The incidence of ETV6-AML1 fusion in 334 unselected Italian and German children with ALL was 18.9%, 7 as compared with 22.5% in 617 children in the UK. 8 Unknown environmental factors may be involved in the generation of t(12;21)-positive ALL occurring in adults, and it is noteworthy that AML1 translocations may occur in therapy-related leukemias arising after exposure to topoisomerase II inhibitors, 9 and that deletion and duplication events occur at the site of ETV6-AML1 recombination, suggesting that staggered double-strand DNA breaks may be at the origin of the translocation.
10 Thus, the interplay between racial and environmental factors may account for the variable incidence of this translocation in different countries. 6 
